Join us for a live webinar presented by HTA in Developing Countries Interest Group (DCIG) “HTA Informing Innovative Drugs’ Market Access in Low- and Middle-Income Countries” on December 2, 3:00 a.m. MST (10:00 a.m. UTC).
The WHO identifies achieving Universal Health Coverage (UHC) as a strategic priority, encompassing a full range of essential health services, of which technology constitutes a core component. It is a significant challenge for many countries, especially low- and middle-income countries (LMICs), to increase their use of scarce public resources to ensure their citizens’ access to innovative pharmaceuticals. The dilemma of high costs, limited access, and UHC calls for innovative approaches and solutions.
This webinar demonstrates how HTA informs innovative drugs market access in different LMICs, and it could address how HTA researchers or HTA institutions respond to the innovative technology with capacity competency. It is a pilot to facilitate HTA communication and collaboration by DCIG. It will map market entry, reimbursement policy for innovative drugs and HTA roles, value frameworks and methodology, institutional challenges, and potential regional/international HTA collaboration.
Speakers will present innovative drugs market entry and reimbursement in different continents, analyzing how HTA is conducted and the value frameworks used in different countries. It will summarize challenges to HTA capacity or competency and information shared with other countries for reference.
- Moderator: Yingyao Chen
- Jeonghoon, from Korea, Korea experience
- Debora Aligieri (Patient representative Brazil)
- Salome Meyer (Patient representative, Cancer Association, South Africa)
- Kiusiang Tay-Teo, (Health Products Policy and Standards Medicines and Health Products, WHO.
- Mouna Jameleddine, INEAS, Tunisia
Join us live on YouTube: https://www.youtube.com/c/HtaiOrg/videos